Open original FDA record ↗Recall record
- FDA identifier
- Z-2557-2018
- Company in FDA record
- Roche Diagnostics Hematology
- FDA record creation date
- Jul 26, 2018
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Discrepant results have been reported in patients with severe microcytic anemia (e.g.iron deficiency, thalassemia) and the following parameters are affected: RBC (red blood cell count), HGB (hemoglobin concentration), MCH (mean corpuscular hemoglobin), HCT (hematocrit), and MCV (mean corpuscular volume).
Source facts
- Action
- An Urgent Field Safety Notice was distributed to customers via email on 5/7/18. The notification included the following actions for to be taken by the customer/user: Until this rule is implemented, when cobas m 511 integrated hematology analyzer displays a HGB value of less than or equal to 9g/dL, Roche advises the user to not report results for the RBC, HGB, MCH, HCT, and MCV parameters. Roche advises the user to perform laboratory confirmatory testing before making transfusion decisions. Delta check against previous results might additionally be used to evaluate the results. For customer evaluating the instrument Roche kindly advises to not report values for diagnostic use until the rule is configured by your Roche Application Specialist.
- Initiated
- 2018-05-07
- Root cause
- Software design
- Terminated
- 2020-05-12
- Distribution
- No distribution in the United States. The devices were distributed to the following foreign countries: Austria, France, Germany, Hong Kong, Japan, Netherlands, Pakistan, Singapore, South Korea, Switzerland, Thailand, and Vietnam.
- Recall number
- Z-2557-2018
- Recall status
- Terminated
- CDRH record ID
- 165298
- FDA record created
- 2018-07-26
- Recall event number
- 80376